In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
The activities of 10 combinations of antifungal agents against 25 clinical isolates of Scopulariopsis brevicaulis were tested by the checkerboard technique. An average indifferent effect was detected for all combinations. Synergy was observed for some isolates and combinations, particularly with posaconazole-terbinafine (68% of strains), amphotericin B-caspofungin (60%), and posaconazole-caspofungin (48%).
Cuenca-Estrella
Manuel
M
Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda (Madrid), Spain. mcuenca-estrella@isciii.es
Gomez-Lopez
Alicia
A
Buitrago
Maria J
MJ
Mellado
Emilia
E
Garcia-Effron
Guillermo
G
Rodriguez-Tudela
Juan L
JL
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D000077336:Caspofungin; D026141:Drug Resistance, Multiple, Fungal; D004357:Drug Synergism; D054714:Echinocandins; D006801:Humans; D066298:In Vitro Techniques; D017964:Itraconazole / Q000494:pharmacology; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D003904:Mitosporic Fungi / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity*; D009281:Naphthalenes / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D000077291:Terbinafine; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D009281:Naphthalenes; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B; D000077336:Caspofungin; D000077291:Terbinafine; D065819:Voriconazole